Phase Ib study of the oral PI3Kδ inhibitor linperlisib in patients with advanced solid tumors
Linperlisib showed an acceptable safety profile and preliminary clinical benefit in patients with a range of advanced solid tumors. Further studies of linperlisib safety and efficacy are warranted.
Authors
- Zusheng Xu (ORCID: https://orcid.org/0000-0002-7266-6202)
- Haibo Mou (ORCID: https://orcid.org/0000-0002-6306-2167)
- Jianzhong Shentu (ORCID: https://orcid.org/0000-0002-7293-9768)
- Yi Feng (ORCID: https://orcid.org/0000-0002-7156-6023)
- Junli Xue (ORCID: https://orcid.org/0000-0002-0564-5284)
- Hanying Bao (ORCID: https://orcid.org/0000-0002-0846-2774)
- Jin Li (ORCID: https://orcid.org/0009-0000-2447-417X)
- Zuhong Xu
- Tianshu Liu (ORCID: https://orcid.org/0000-0002-8604-6311)
- Yongmei Yin (ORCID: https://orcid.org/0000-0003-0225-1471)
- Nong Xu (ORCID: https://orcid.org/0000-0001-7499-0383)
- Jianjin Huang
- Jun Zhang (ORCID: https://orcid.org/0000-0002-3067-2620)
Institutions
- Sun Yat-sen University (CN)
- Shanghai Jiao Tong University (CN)
- Fudan University (CN)
- Ruijin Hospital (CN)
- Zhongshan Hospital (CN)
- Shanghai East Hospital (CN)
- The First Affiliated Hospital, Sun Yat-sen University (CN)
- Second Affiliated Hospital of Zhejiang University (CN)
- Jiangsu Provincial Hospital of Traditional Chinese Medicine (CN)
- First Affiliated Hospital Zhejiang University (CN)
Publication Details
- Journal
- International Journal of Clinical Oncology
- Published
- 2024-11-13
- DOI
- https://doi.org/10.1007/s10147-024-02657-2
- Primary Topic
- PI3K/AKT/mTOR signaling in cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00